EGFR and cancer: Consistent with the imputed drug response in the TCGA cohort, cancer cells with higher complement scores were more likely to be sensitive to drugs targeting EGFR and PI3K signaling pathways, and resistant to drugs that target PLK3 and chromatin histone acetylation (Figure 7D, andSuppelmentary Figure S11A).